vaccinated. it will make it easier for these organizations to come to a decision to mandate these vaccines. dr. hotez, what happens once the fda gives approval? what is the next step? well, i think it s important to point out that the fda doesn t unilaterally just do this. i think there s some steps. they re going to have to or will consult with the committee, the vaccines and related biologics committee, for their input and take their advice. so, i think that s a step. and of course they will consult with the centers for disease control and the acip. so, this is not a one-day thing. i think it s going to take a little bit of time to move all those processes through. but i think it eventually will happen and it s going to have very important implications, certainly as dr. adams points out. but i think there s another really important piece here. that is it s a tremendous validation for the work of the fda. you know, the fda was under
vaccinated. to put it plainly, it will make it easier for these organizations to come to a decision to mandate these vaccines. dr. hotez, what happens once the fda gives approval? what is the next step? well, i think it s important to point out that the fda doesn t unilaterally just do this. i think there s some steps. they re going to have to or will consult with the committee, the vaccines and related biologics committee, for their input and take their advice. so, i think that s a step. and of course they will consult with the centers for disease control and the acip. so this is not a one-day thing. i think it s going to take a little bit of time to move all those processes through. but i think it eventually will happen and it s going to have very important implications, certainly as dr. adams points out. but i think there s another really important piece here. that is it s a tremendous validation for the work of the
reviewed by acip to really look through the data because none of us have seen adequate amounts of data. that s point one. point two is when we talk about global vaccine equity, and i have devoted my life to developing vaccines for poverty-related and neglected diseases including a covid vaccine that our group at texas children s is now accelerating in india. india has produced starting to produce 100 million doses a month of that vaccine. i think the problem is we don t have enough mrna vaccine to go around. i mean the brand-new technology, there s a learning curve before you can scale it up and make billions of doses. i think the failure was a science policy failure, being so focused on innovation and what i sometimes in my despair call shiny, new toys. they re good vaccines. i got the pfizer-biontech vaccine and i m grateful for it, but there never would be enough in 2021 to vaccinate the world. so now we re getting calls from you name it, countries in africa and asia desperate for